Survey: U.S. neurologists would prescribe Leqembi if fully approved
By
Alicia Lasek
Apr 12, 2023
A “healthy proportion” of surveyed neurologists have already begun prescribing the treatment, and nearly all said they planned to do so if traditional FDA approval is granted.
Clinical Briefs for Wednesday, Nov. 6
By
Alicia Lasek
Nov 05, 2019
Single odds-defying case may lead to new Alzheimer’s treatments … Fully digital Alzheimer’s study to track risk factors in 400,000 volunteers … Blood samples may identify those at risk for frailty...
Clinical briefs for Tuesday, May 11
By
Alicia Lasek
May 11, 2021
Dementia diagnoses and mental health service use drop among elders during pandemic … Alzheimer’s patients’ depression scores rose after pandemic lockdown … Fully 71% of U.S. seniors now vaccinated...
Nearly half of Alzheimer’s cases are mild, supporting a focus on early intervention
By
Alicia Lasek
Jan 14, 2021
The great prevalence of mild disease underscores the need for interventions that may slow decline or prevent progression in dementia, researchers contend.
Alzheimer’s signs may be evident decades before onset: Family history is key
By
Alicia Lasek
Jun 23, 2019
Signs of Alzheimer’s disease may show up four decades before onset, according to a web-based study of 60,000 individuals.
Amyloid brain plaques not a sure sign of Alzheimer’s, researchers find
By
Alicia Lasek
Jan 12, 2023
A new study challenges the theory that an increase in brain amyloid protein signals Alzheimer’s disease. The findings may be especially relevant to clinicians as amyloid-targeting drugs such as Leqembi...